1-9 of 9
Todd L. Rosenblat, MD, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Alexander Coltoff, MD, Joseph G. Jurcic, MD, Peter Campbell, PharmD, BCOP, Daniel J. Lee, MD, Mark L Heaney, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD MS, Mark G. Frattini, MDPhD, George Vlad, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–14.
https://doi.org/10.1182/blood-2020-134237
Published: 2020
Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2957.
https://doi.org/10.1182/blood-2019-129962
Published: 2019
Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3899.
https://doi.org/10.1182/blood-2019-130203
Published: 2019
Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3846.
https://doi.org/10.1182/blood-2019-129845
Published: 2019
Journal Articles

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine J. Walsh, MD, Michael R. Savona, MD, Hagop M. Kantarjian, MD, Patricia L. Kropf, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Naval G. Daver, MD, Elias J. Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph Mace, MD, Nikolai A. Podoltsev, MD PhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Sue Naim, Yong Hao, MD, Mohammad Azab, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 231.
https://doi.org/10.1182/blood-2018-99-110465
Published: 2018
Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2816.
https://doi.org/10.1182/blood.V128.22.2816.2816
Published: 2016
Journal Articles

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Karen W.L. Yee, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Nikolai A. Podeltsev, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Wendy Stock, MD, Michael R. Savona, MD, Todd L. Rosenblat, MD MS, Jesus G. Berdeja, MD, Laksmi Wilson, James N. Lowder, MD, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 458.
https://doi.org/10.1182/blood.V126.23.458.458
Published: 2015
Journal Articles

High Mitochondrial Membrane Potential Identifies Patients with Myeloproliferative Neoplasms with a More Aggressive Natural History

Jeffrey R Gardner, MBA, Omar Abdel-Wahab, Mark Frattini, MD, Joseph G Jurcic, MD, Kristina Knapp, Todd L. Rosenblat, MD, MS, Gerald A. Soff, MD, Ross Levine, MD, Mark Heaney, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1992.
https://doi.org/10.1182/blood.V116.21.1992.1992
Published: 2010
Journal Articles

A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry In the United States Between 1992–2007

Jae H. Park, MD, Katherine S Panageas, DrPH, Maria J Schymura, PhD, Baozhen Qiao, PhD, Joseph G Jurcic, MD, Todd L. Rosenblat, MD, MS, Jessica K Altman, MD, Dan Douer, MD, Jacob M. Rowe, Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 872.
https://doi.org/10.1182/blood.V116.21.872.872
Published: 2010